Immunotherapy & Immuno-Oncology
Part of Healthcare - Oncology
 JNJ | Johnson & Johnson | $0.5t | $254.38 | +4.0% | 9.7M |
 ABBV | ABBVIE INC. | $384.7b | $252.95 | +4.1% | 11.1M |
 MRK | Merck & Co., Inc. | $293.2b | $128.22 | +1.7% | 9.8M |
 AZN | AstraZeneca PLC | $287.9b | $188.18 | +1.5% | 2.5M |
 AMGN | Amgen Inc | $181.8b | $357.17 | +1.4% | 1.7M |
 BMY | Bristol-Myers Squibb Co. | $116.8b | $57.40 | +3.8% | 9.2M |
 REGN | Regeneron Pharmaceuticals Inc | $64.5b | $629.25 | +2.1% | 689.1K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | $24.7b | $55.59 | +2.9% | 4.4M |
 MRNA | Moderna, Inc. Common Stock | $18.7b | $67.14 | +12.6% | 12.8M |
 IBRX | ImmunityBio, Inc. Common Stock | $7.9b | $8.48 | +11.6% | 23.1M |
 ACLX | Arcellx, Inc. Common Stock | $6.7b | $115.06 | -0.0% | 16.1M |
 CGON | CG Oncology, Inc. Common stock | $5.5b | $72.01 | -1.3% | 1.4M |
 RCUS | Arcus Biosciences, Inc. | $3.2b | $31.36 | +2.5% | 1.6M |
 NKTR | Nektar Therapeutics | $2.2b | $63.62 | +2.4% | 1.1M |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | $1.8b | $4.24 | +0.4% | 10.9M |
 SNDX | Syndax Pharmaceuticals, Inc. | $1.7b | $21.15 | +7.6% | 2.0M |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | $1.7b | $12.21 | +17.7% | 15.4M |
 IMTX | Immatics N.V. Ordinary Shares | $1.6b | $9.53 | +0.2% | 207.1K |
 PGEN | Precigen, Inc. Common Stock | $1.5b | $5.82 | +6.2% | 5.8M |
 INBX | Inhibrx Biosciences, Inc. Common Stock | $1.5b | $94.73 | -0.9% | 289.0K |
 BCAX | Bicara Therapeutics Inc. Common Stock | $1.4b | $26.85 | +2.1% | 1.5M |
 CRVS | Corvus Pharmaceuticals, Inc. | $1.0b | $13.29 | +3.3% | 1.3M |
 CGEM | Cullinan Therapeutics, Inc. Common Stock | $1.0b | $17.93 | -0.8% | 823.6K |
 JANX | Janux Therapeutics, Inc. Common Stock | $0.9b | $14.67 | +2.3% | 2.1M |
 XNCR | Xencor, Inc. | $0.9b | $15.32 | +2.4% | 929.6K |
 OMER | Omeros Corporation | $0.8b | $8.64 | -19.2% | 8.7M |
 CTMX | CytomX Therapeutics, Inc. | $0.8b | $3.38 | +3.4% | 3.6M |
 AURA | Aura Biosciences, Inc. Common Stock | $0.8b | $7.00 | +1.6% | 479.1K |
 REPL | Replimune Group, Inc. | $0.7b | $11.63 | +4.4% | 7.4M |
 CADL | Candel Therapeutics, Inc. Common Stock | $0.6b | $9.70 | +3.4% | 1.6M |
 CBIO | Crescent Biopharma, Inc. Common Stock | $0.6b | $17.99 | +8.0% | 350.4K |
 CMPX | Compass Therapeutics, Inc. Common Stock | $428.6m | $2.07 | +1.4% | 3.3M |
 GLSI | Greenwich LifeSciences, Inc. | $362.6m | $19.75 | +8.5% | 160.7K |
 MGNX | MacroGenics, Inc. | $264.4m | $4.67 | +3.0% | 993.2K |
 CNTX | Context Therapeutics Inc. Common Stock | $261.9m | $0.58 | +5.7% | 4.6M |
 ALXO | ALX Oncology Holdings Inc. Common Stock | $255.7m | $2.02 | +12.8% | 1.5M |
 CGEN | Compugen Ltd | $248.8m | $2.09 | +4.0% | 284.4K |
 CHRS | Coherus Oncology, Inc. Common Stock | $245.3m | $1.50 | +0.7% | 655.9K |
 ELTX | Elicio Therapeutics, Inc. Common Stock | $218.3m | $3.98 | +6.3% | 611.3K |
 INDP | Indaptus Therapeutics, Inc. Common Stock | $199.3m | $3.42 | +4.9% | 127.2K |
 AGEN | Agenus Inc. | $145.7m | $3.06 | +5.2% | 534.9K |
 HURA | TuHURA Biosciences, Inc. Common Stock | $143.9m | $2.23 | -14.1% | 659.4K |
 GNLX | Genelux Corporation Common Stock | $136.8m | $3.23 | -1.0% | 303.6K |
 ONCY | Oncolytics Biotech, Inc. Common Shares | $124.1m | $0.94 | +3.7% | 753.2K |
 ANIX | Anixa Biosciences, Inc. | $90.5m | $2.86 | +5.5% | 988.9K |
 CUE | Cue Biopharma, Inc. | $88.6m | $25.13 | -1.7% | 68.2K |
 MAIA | MAIA Biotechnology, Inc. | $84.5m | $1.36 | +4.4% | 266.8K |
 XBIT | XBiotech Inc | $73.8m | $2.32 | -0.4% | 54.8K |
 BYSI | BeyondSpring Inc. Ordinary Shares | $69.1m | $1.69 | +2.8% | 31.1K |
 PDSB | PDS Biotechnology Corporation Common Stock | $62.0m | $0.90 | -2.1% | 560.9K |